Sandoz Antitrust Claims Nixed In Bayer’s Yasmin IP Suit

Law360, New York (September 28, 2011, 6:43 PM EDT) -- A New York federal judge on Wednesday dismissed antitrust counterclaims brought by drugmaker Sandoz Inc. in Bayer Schering Pharma AG’s patent infringement suit over a generic version of oral contraceptive Yasmin, effectively ending the dispute.

Bayer originally brought the suit in April 2008, seeking to block Sandoz and Watson Pharmaceuticals Inc. from marketing a generic version of the oral contraceptive.

Despite winning a judgment of noninfringement in September 2010, Sandoz had pressed ahead with its counterclaims alleging Sherman Act violations by Bayer and accusing the Leverkusen,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.